unpopular opinion: most of what gets said here about phase 2 is guesswork
unpopular opinion: most of what gets said here about phase 2 is guesswork. Change my mind, genuinely — I have no stake in being right about this. The standing caveat, written out properly because it keeps getting compressed into a footnote. Nothing containing this compound is approved by any regulator.…
Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.
Agreed on the heart-rate reports. They are consistent enough across the threads to be worth noting, not enough to be a finding.
That reads as a titration plan for an unapproved compound. This board cannot host that and it should not want to.
the TRIUMPH programme is still running, so anything definitive is premature
not approved anywhere, which is the single most important fact in this board
The injection-site soreness profile felt different rather than worse. Hard to describe and impossible to quantify, so take it as an impression.
the phase 2 numbers were striking and they were also 48 weeks in a small population
The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.